Year All20232022202120202019201820172016201520142013201220112009 Feb 21, 2023 REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights Feb 17, 2023 REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023 Feb 11, 2023 REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process Feb 08, 2023 REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference Feb 06, 2023 REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference Jan 23, 2023 REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients Jan 09, 2023 REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
Feb 21, 2023 REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Feb 11, 2023 REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process
Feb 08, 2023 REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference
Feb 06, 2023 REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference
Jan 23, 2023 REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
